Display Settings:

Format

Send to:

Choose Destination
    Chest. 2012 Jan 12. [Epub ahead of print]

    Prognostic significance of extent of visceral pleural invasion in completely resected node-negative non-small cell lung cancer with visceral pleural invasion.

    Source

    1Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan.

    Abstract

    ABSTRACT

    OBJECTIVE:

    Visceral pleural invasion (VPI) has been defined as invasion beyond the elastic layer (PL1) including invasion to the visceral pleural surface (PL2). The aim of this study is to evaluate the prognostic factors and patterns of recurrence in resected node-negative non-small cell lung cancer (NSCLC) with VPI.

    METHODS:

    We retrospectively reviewed the clinicopathologic characteristics of 355 patients of resected node-negative NSCLC with VPI at Taipei Veterans General Hospital between 1990 and 2006. The prognostic value and patterns of recurrence were analyzed, and were compared between PL1 and PL2 groups.

    RESULTS:

    The median follow-up time was 54.2 months. The 5-year overall survival rate and probability of freedom from recurrence were 61.9% and 66.2%, respectively. The extent of VPI was PL1 in 300 (84.5%) and PL2 in 55 (15.5%) patients. During follow-up, 107 (30.1%) patients developed recurrence. The patterns of recurrence included local recurrence only in 20 (18.7%), distant metastasis only in 59 (55.1%), and both local and distant in 28 (26.2%) patients. Thirteen (12.1%) of the 107 patients with recurrence developed malignant pleural effusion. The percentage of malignant pleural effusion in PL2 group was significantly higher than that in PL1 group (P = 0.006). Patients with PL2 had significantly worse overall survival (P = 0.046) and lower probability of freedom from recurrence (P = 0.028) in multivariate analysis.

    CONCLUSIONS:

    PL2 was a significant prognostic factor for recurrence and worse overall survival in node-negative NSCLC with VPI. This information is important for further design of clinical trials for aggressive adjuvant therapy.

    PMID:
    22241763
    [PubMed - as supplied by publisher]

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk